Next 10 |
2024-05-09 19:58:06 ET Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Conference Call May 09, 2024 04:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer ...
2024-05-09 16:03:28 ET More on Achieve Life Sciences Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript Jones starts Achieve Life Sciences at buy, cites market ...
SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its f...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-07 08:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting April 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling id...
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and excellent compliance to study treatment Achieve expects to conduct an End-of...
LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las Vegas, NV. Event website: https://planetmi...
2024-04-26 17:01:59 ET More on Achieve Life Sciences Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns Achieve Life Sciences stock falls 11% amid FDA update, securities sale Seeking Alpha’s Quant Rating on Achieve Life S...
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it ...
2024-04-17 17:41:31 ET More on Achieve Life Sciences Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript Achieve Life Sciences stock falls 11% amid FDA update, s...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its f...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and excellent compliance to study treatment Achieve expects to conduct an End-of...